BNP Paribas Asset Management’s GreenLight Biosciences Holdings, PBC Common Stock GRNA Stock Holding History

BNP Paribas Asset Management’s Portfolio GRNA Stock Details GRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-1,269,179	Closed	-$378K	–	875
2023 Q2	$378K	Buy	1,269,179 +564,255	+80%	+$170K	﹤0.01%	799
2023 Q1	$305K	Sell	704,924 -250,546	-26%	-$192K	﹤0.01%	838
2022 Q4	$1.13M	Sell	955,470 -145,748	-13%	-$237K	﹤0.01%	762
2022 Q3	$2.56M	Buy	1,101,218 +975,746	+778%	+$2.55M	0.01%	651
2022 Q2	$277K	Buy	125,472 +19,363	+18%	+$134K	﹤0.01%	894
2022 Q1	$1.02M	Buy	+106,109	New	+$951K	﹤0.01%	731

BNP Paribas Asset Management's GRNA Position: Q3 2023 in Review

BNP Paribas Asset Management sold out of GreenLight Biosciences Holdings, PBC Common Stock (GRNA) in Q3 2023, closing a stake of 1,269,179 shares — an estimated $378K sold.

BNP Paribas Asset Management first reported a position in GRNA in Q1 2022 and held it in 6 quarters. The position peaked at $2.56M in Q3 2022. 0 funds tracked by Wall St. Rank hold GRNA as of Q3 2023.

BNP Paribas Asset Management reported no remaining GreenLight Biosciences Holdings, PBC Common Stock position as of Q3 2023 after selling out during the quarter.
BNP Paribas Asset Management sold 1,269,179 GreenLight Biosciences Holdings, PBC Common Stock shares in Q3 2023, an estimated $378K.
BNP Paribas Asset Management first reported a position in GreenLight Biosciences Holdings, PBC Common Stock in Q1 2022 and held it in 6 quarters.
BNP Paribas Asset Management's GreenLight Biosciences Holdings, PBC Common Stock position peaked at $2.56M in Q3 2022.
0 funds tracked by Wall St. Rank held GreenLight Biosciences Holdings, PBC Common Stock as of Q3 2023.

Based on BNP Paribas Asset Management's 13F filing for Q3 2023, filed 13 Nov 2023.